“Developing new therapies for this subset of ovarian cancer patients is urgently needed. DENALI Part 1b results are exciting as they show that the WEE1 inhibitor, azenosertib, is active in a Cyclin E1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback